ClinicalTrials.gg
RecruitingNCT07855172Updated Nov 10, 2026

Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)

A Phase 1/2 interventional study of Hexavalent (DTwP-HepB-rPV-Hib) Vaccine and HEXASIIL in Diptheria Immunization, Tetanus Immunization and Pertussis Immunization, sponsored by Serum Institute of India Pvt. Ltd.. Recruiting at 1 site in Bangladesh. Open to participants aged 6 Weeks to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Serum Institute of India Pvt. Ltd. · Phase 1/2, Interventional, and Prevention

Updated Nov 10, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
6 Weeks to 24 Months
Sex
All
01

Study summary

This is a Phase I/II, double-blind, randomized, active controlled, multi-centric clinical trial to assess the reactogenicity, safety and immunogenicity of a SIIPL DTwP-HepB-rPV-Hib vaccine in comparison with HEXASIIL® in healthy toddlers and infants. This trial is planned as a Phase I/II trial with two age cohorts to be enrolled sequentially, starting with healthy toddlers and subsequently extending to healthy infants.

In Phase I of the trial, after at least one parent signs the informed consent and the participant's eligibility is confirmed, healthy toddlers aged 12-24 months will be randomized in a 2:1 ratio, to receive 0.5 mL of either of the vaccines intramuscularly in the upper anterolateral aspect of the thigh. Following vaccination, all toddlers will be observed at the site for minimum 30 (+15) minutes for any Iimmediate Adverse Event (IAE). Solicited Adverse Events (AEs) will be actively collected for 7 days post vaccination. Unsolicited AEs and Serious AEs will be collected throughout the trial from the time of signing informed consent till 28 days post vaccination. Blood samples for immunogenicity assessment will be obtained from all participating toddlers at Visit 1 (Prior to vaccination) and at Visit 4.

A Data Safety Monitoring Board (DSMB) meeting will be convened for the evaluation of 7-day safety data in all participants. The DSMB shall review the safety data and provide recommendations to initiate Phase II of the trial. Additionally, Safety Review Comitte (SRC) will review the 24-hour safety data from the initial sentinel group (three participants) and give advice on progression to the subsequent enrolment in Phase I.

After at least one parent signs the informed consent and the participant's eligibility is confirmed, all infants will be randomized in 2:1 ratio to receive a 3-dose primary vaccination series at 6, 10 and 14 weeks of age. Each participant will receive 0.5 mL of either vaccine intramuscularly in the upper anterolateral aspect of the thigh. Following each vaccination, all infants will be observed at the site for minimum 30 (+15) minutes for any IAEs. Active follow up for solicited AEs will be conducted over the 7-day period after each vaccination. Unsolicited AE/SAEs will be collected from signing of informed consent till Visit 10. Blood samples for immunogenicity assessment will be obtained from all participating infants at Visit 1 (Prior to vaccination) and at Visit 10.

02

Conditions studied

  • Diptheria Immunization
  • Tetanus Immunization
  • Pertussis Immunization
  • Hepatitis B Immunization
  • Haemophilus InfluenzaeType B Immunization
  • Polio Immunization

Keywords

  • hexavalent
  • phase I
03

In context

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

This study's planned enrollment of 186 is above the median of 145 across 756 interventional studies indexed under Hepatitis B.

Browse Hepatitis B studies →

Lead sponsor

Serum Institute of India Pvt. Ltd. is the lead sponsor of 26 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Weeks to 24 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1

  1. Male or female toddlers aged between 12-24 (both inclusive) months on the day of vaccination, who have completed primary immunization series against diphtheria, tetanus, pertussis, , poliomyelitis (Oral Polio Vaccine [OPV] and/or Inactivated Polio Vaccine [IPV]) and Haemophilus influenzae type b at least 6 months prior to enrolment and have not received the booster dose for the above-mentioned vaccines.
  2. Toddlers in good health, as determined by their medical history, physical examination and the clinical judgment of the Investigator.
  3. Toddlers with weight-for-length z-score is ≥ -2 Standard Deviation (SD) at the time of enrolment.
  4. Toddler's parent(s) willingness and ability to comply with the requirements of the protocol.
  5. signed by at least one parent.

Phase 2

  1. Male or female infants aged 6-8 weeks at the time of first vaccination.
  2. Infants with good health, as determined by the medical history, physical examination and clinical judgment of the Investigator.
  3. Infants who are OPV naive.
  4. Informed consent form signed by at least one parent.
  5. Infants born at full term pregnancy (≥ 37 weeks).
  6. Infants with weight-for-length z-score ≥ -2 SD at the time of enrolment.
  7. Willingness of participant's parent(s) to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

Phase 1

  1. History of diphtheria/tetanus/pertussis//Haemophilus influenzae type b/poliomyelitis infection(s).
  2. Presence of fever ≥ 38°C/100.4°F within 48 hours.
  3. Acute illness of moderate to severe intensity according to the clinical judgment of the investigator.
  4. History of administration of any or non-registered product (drug or vaccine) within 4 weeks prior to administration of IMPs or planned during the course of trial participation.
  5. Administration of any vaccine (except OPV during government immunization campaign) in the 4 weeks preceding the IMP administration or planned receipt of any vaccine during the trial participation period.
  6. History of anaphylaxis, or any serious vaccine reaction, or /allergy to any vaccine or components of IMPs.
  7. History of following events that are known to have occurred in temporal relation to receipt of pertussis-containing vaccine:

    • temperature ≥40°C within 48 hours of vaccination, not due to another identifiable cause.
    • collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of vaccination.
    • persistent, inconsolable crying lasting ≥ 3 hours, occurring within 48 hours of vaccination.
  8. History of major congenital defects or developmental disorders or genetic diseases as determined by medical history or clinical assessment.
  9. History of thrombocytopenia or a bleeding disorder following IM administration.
  10. History or current evidence of any chronic disease that in the opinion of the Investigator might interfere with the evaluation of trial objectives.
  11. Receipt of a blood transfusion, other blood products, or immunoglobulins in 3 months prior to IMP administration, or planned administration during the active trial period.
  12. Receipt of antibiotics in the past 3 days.
  13. Family history of any medical conditions, that in the investigator's opinion, could affect the trial outcomes.
  14. Presence of evolving or changing neurological disorder or toddler with a history of seizures and/or encephalopathy.
  15. Known personal or maternal history of (HIV), Hepatitis B or seropositivity.
  16. Planned surgery during the trial.
  17. Toddlers with a known or suspected impairment of the immune function, or those receiving therapy such as anti-cancer chemotherapy or radiation therapy or received immunosuppressive therapy within 3 months prior to entry in the trial.
  18. Participation in another clinical trial 4 weeks preceding the trial enrolment or planned participation during the present trial period in another clinical trial.
  19. Toddlers whose families are planning to leave the area of the trial site before the end of the trial period.

Phase 2

  1. History of diphtheria/tetanus/pertussis/hepatitis B/Haemophilus influenzae type b/poliomyelitis infection(s).
  2. Presence of fever ≥ 38°C/100.4°F within 48 hours.
  3. Previous vaccination or planned receipt of any vaccine against diphtheria, tetanus, pertussis, hepatitis B (except birth dose), poliomyelitis or Haemophilus influenzae type b infection apart from IMPs during the trial period.
  4. Acute illness of moderate to severe intensity according to the clinical judgment of the investigator.
  5. Administration of any vaccine in the 4 weeks (except BCG) preceding the first dose of IMP administration.
  6. Receipt of antibiotics in the past 3 days.
  7. History of major congenital defects or illness that require medical therapy, as determined by medical history or clinical assessment.
  8. History of any clinically significant chronic disease that in the opinion of the Investigator, might interfere with the evaluation of the trial objectives.
  9. History of anaphylaxis, or any serious vaccine reaction, or hypersensitivity/allergy to any vaccine or components of IMP.
  10. Infants with a known or suspected impairment of the immune function, or those receiving immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy or received immunosuppressive therapy prior to trial entry.
  11. Presence of evolving or changing neurological disorder or infant with a history of seizures and/or encephalopathy.
  12. Known thrombocytopenia or a bleeding disorder.
  13. Planned surgery during the trial.
  14. Known personal or maternal history of HIV, Hepatitis B or Hepatitis C seropositivity.
  15. Receipt of blood or blood-derived products or immunoglobulins or planned administration during the trial which might interfere with the assessment of the immune response.
  16. Participation in another clinical trial 4 weeks preceding the trial enrolment or planned participation during the present trial period in another clinical trial.
  17. Infants whose families are planning to leave the area of the trial site before the end of the trial period.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    Hexavalent (DTwP-HepB-rPV-Hib) Vaccine

    Hexavalent (DTwP-HepB-rPV-Hib) Vaccine for active immunization of infants and toddlers

    Biological: Hexavalent (DTwP-HepB-rPV-Hib) Vaccine

  • Active comparator
    HEXASIIL

    Hexavalent (DTwP-HepB-IPV-Hib) Vaccine for active immunization of infants and toddlers

    Biological: HEXASIIL

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence, severity and relationship of solicited AEs occurring up to 7 days following vaccination, unsolicited AEs and Serious Adverse Events till 28 days following vaccination in toddlers

    Time frame: 28 days

  2. The incidence, severity and relationship of solicited AEs occurring up to 7 days following each vaccination, unsolicited AEs and SAEs till 28 days post completion of a 3-dose primary vaccination series in infants

    Time frame: 28 days post last dose

Secondary outcomes

  1. Percentage of toddlers achieving seroprotection for diphtheria, tetanus, hepatitis B, Haemophilus influenzae type b, poliovirus types 1, 2 & 3 and seroconversion/seropositivity for pertussis and, 28 days following vaccination

    Time frame: 28 days

  2. Percentage of infants achieving seroprotection for diphtheria, tetanus, hepatitis B, Hib, seroprotection and seroconversion for poliovirus types 1, 2 & 3 and seroconversion/seropositivity for pertussis and, 28 days post completion of 3 doses.

    Time frame: 28 days after last dose

  3. Geometric mean concentrations/titres (GMCs/GMTs) of anti-diphtheria, anti-tetanus, anti-pertussis, anti-HBsAg, anti-PRP (polyribosyl ribitol phosphate) and anti-polio types 1, 2 & 3 antibodies, 28 days following vaccination in toddlers

    Time frame: 28 days

  4. Geometric mean concentrations/titres (GMCs/GMTs) of anti-diphtheria, anti-tetanus, anti-pertussis, anti-HBsAg, anti-PRP and anti-polio types 1, 2 & 3 antibodies, 28 days post completion of a 3-dose primary vaccination series in infants.

    Time frame: 28 days after last dose

07

Study locations

1 of 1 sites recruiting
  • International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
    Dhaka, 1212, Bangladesh
    Recruiting
    • K. Zaman · Contactkzaman@icddrb.org · +880-1713047100
    • K. Zaman, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Summary results

Supporting information: Study protocol

Access criteria: Researchers who provide a methodologically sound proposal may be provided the access after Sponsor permission and if signed data-access agreements are in place.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Oct 2027, 11 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 2, 2026
StartActual
Nov 1, 2026was Oct 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) is now Recruiting
Nov 10, 2026
Start date
Oct 2026→Nov 1, 2026 (actual)
Nov 10, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) is now Recruiting
    Start date Oct 2026→Nov 1, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 6, 2026
    Minor edits only
    + 2 other changes: verification date and contact details
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855172
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Nov 1, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Hitt Sharma
Contact
drhjs@seruminstitute.com
+912026602451
Sameer Parekh
Contact
sameer.parekh@seruminstitute.com
+912026602139
Hitt Sharma
study director · Serum Institute of India Pvt. Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vaccines, Combined

Start the discussion